Vaxcell-Bio Therapeutics Co., Ltd.
Financials
Valuation Metrics
Vaxcell-Bio Therapeutics Co., Ltd.'s Market Cap is ₩988B. At end of 2025 it was ₩2323B. Ranked #1251 of 2,436 in KR market (top 51%), #674 of 1,649 on KOSDAQ (top 41%), #141 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 60%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 98.84B KRW | KR#1,251/2,436 Sec#141/234 |
| Revenue | 6.87B KRW | KR#2,324/2,436 Sec#188/234 |
| Net Income | -14.69B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 63.60B KRW | KR#2,051/2,436 Sec#176/234 |
| Net Assets | 57.22B KRW | KR#1,782/2,436 Sec#153/234 |
| Employees | 81 | KR#1,786/2,436 Sec#147/234 |
| Value | ||
| P/B | 1.73x | KR#1,882/2,436 Sec#136/234 |
| P/S | 14.38x | KR#2,309/2,436 Sec#172/234 |
| FCF Yield | -16.87% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -25.68% | KR#2,131/2,436 Sec#169/234 |
| ROA | -23.10% | KR#2,252/2,436 Sec#183/234 |
| Op. Margin | -230.16% | KR#2,348/2,436 Sec#191/234 |
| Revenue Growth | -10.70% | KR#1,891/2,436 Sec#173/234 |
| Financial Health | ||
| Debt Ratio | 11.15% | KR#16/2,436 Sec#6/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -16.67B KRW | KR#1,858/2,436 Sec#174/234 |
| Cash | 10.37B KRW | KR#1,653/2,436 Sec#131/234 |
| Current Ratio | 6.15x | KR#217/2,436 Sec#48/234 |
| Performance | ||
| 1Y Return | -54.45% | KR#2,154/2,436 Sec#203/234 |
| 1M Return | -6.39% | KR#1,511/2,436 Sec#154/234 |
| From 52W High | -63.11% | KR#1,867/2,436 Sec#158/234 |
| 1Y MDD | -67.41% | KR#1,814/2,436 Sec#151/234 |
| Trading | ||
| Volume | 142,367 shares | KR#745/2,436 Sec#71/234 |
| Foreign Own. | 5.67% | KR#732/2,436 Sec#72/234 |
| Per Share | ||
| EPS | -632 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,469 KRW | KR#1,915/2,436 Sec#154/234 |
Company Info
Established in 2010 as a specialized company for developing anticancer immunotherapeutics, the company was listed on the KOSDAQ market in 2020. It has built diverse pipelines, including the innate immune system-based Vax-NK anticancer immunotherapy platform, the next-generation Vax-CAR series platform, small molecule compound targeted anticancer drugs, bispecific antibody new drugs, DDS-based drug development, and a pet healthcare business. The company continuously innovates to realize its vision of a better world through immunotherapies, focusing on key elements of the immune system. Vaxcell-Bio was established in 2010 and is headquartered in Jeollanam-do, Hwasun-gun.